Nephrometry scores to predict oncological outcomes following partial nephrectomy (UroCCR Study 70).


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 19 04 2023
accepted: 11 09 2023
medline: 4 12 2023
pubmed: 4 10 2023
entrez: 4 10 2023
Statut: ppublish

Résumé

Partial nephrectomy (PN) for large or complex renal tumors can be difficult and associated with a higher risk of recurrence than radical nephrectomy. We aim to evaluate the clinical useful of nephrometry scores for predicting oncological outcomes in a large cohort of patients who underwent PN for renal cell carcinomas. Our analysis included patients who underwent PN for renal cell carcinoma in 21 French academic centers (2010-2020). RENAL, PADUA, and SPARE scores were calculated based on preoperative imaging. Uni- and multivariate cox models were performed to identify predictors of recurrence-free survival and overall survival. The area under the curve (AUC) was used to identify models with the highest discrimination. Decision curve analyses (DCAs) determined the net benefit associated with their use. A total of 1927 patients were analyzed with a median follow-up of 32 months (14-45). RENAL score (p = 0.01), age (p = 0.002), histological type (p = 0.001), high nuclear grade (p = 0.001), necrotic component (p < 0.001), and positive margins (p = 0.005) were significantly related to recurrence in multivariate analyses. The discriminative performance of the 3 radiological scores was modest (65, 63, and 63%, respectively). All 3 scores showed good calibration, which, however, deteriorated with time. Decision curve analysis of the three models for the prediction of overall and recurrence-free survival was similar for all three scores and of limited clinical relevance. The association between nephrometry scores and oncological outcomes after NP is very weak. The use of these scores for predicting oncological outcomes in routine practice is therefore of limited clinical value.

Identifiants

pubmed: 37792008
doi: 10.1007/s00345-023-04633-3
pii: 10.1007/s00345-023-04633-3
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3559-3566

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S et al (2019) European Association of Urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol 75(5):799–810
doi: 10.1016/j.eururo.2019.02.011 pubmed: 30803729
Thompson RH, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED, Cheville JC et al (2008) Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol 179(2):468–471
doi: 10.1016/j.juro.2007.09.077 pubmed: 18076931
Patard JJ, Baumert H, Bensalah K, Bernhard JC, Bigot P, Escudier B et al (2013) CCAFU Recommendations 2013: Renal cancer. Progres En Urol J Assoc Francaise Urol Soc Francaise Urol 23(Suppl 2):S177-204
Badalato GM, Kates M, Wisnivesky JP, Choudhury AR, McKiernan JM (2012) Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach. BJU Int 109(10):1457–1462
doi: 10.1111/j.1464-410X.2011.10597.x pubmed: 21933334
Weight CJ, Larson BT, Fergany AF, Gao T, Lane BR, Campbell SC et al (2010) Nephrectomy induced chronic renal insufficiency is associated with increased risk of cardiovascular death and death from any cause in patients with localized cT1b renal masses. J Urol 183(4):1317–1323
doi: 10.1016/j.juro.2009.12.030 pubmed: 20171688
Delto JC, Paulucci D, Helbig MW, Badani KK, Eun D, Porter J et al (2018) Robot-assisted partial nephrectomy for large renal masses: a multi-institutional series. BJU Int 121(6):908–915
doi: 10.1111/bju.14139 pubmed: 29357404
Ficarra V, Novara G, Secco S, Macchi V, Porzionato A, De Caro R et al (2009) Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. Eur Urol 56(5):786–793
doi: 10.1016/j.eururo.2009.07.040 pubmed: 19665284
Kutikov A, Uzzo RG (2009) The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol 182(3):844–853
doi: 10.1016/j.juro.2009.05.035 pubmed: 19616235
Ficarra V, Porpiglia F, Crestani A, Minervini A, Antonelli A, Longo N et al (2019) The Simplified PADUA REnal (SPARE) nephrometry system: a novel classification of parenchymal renal tumours suitable for partial nephrectomy. BJU Int 124(4):621–628
doi: 10.1111/bju.14772 pubmed: 30963680
Camacho JC, Kokabi N, Xing M, Master VA, Pattaras JG, Mittal PK et al (2015) R.E.N.A.L. (Radius, exophytic/endophytic, nearness to collecting system or sinus, anterior/posterior, and location relative to polar lines) nephrometry score predicts early tumor recurrence and complications after percutaneous ablative therapies for renal cell carcinoma: a 5-year experience. J Vasc Interv Radiol JVIR 26(5):686–693
doi: 10.1016/j.jvir.2015.01.008 pubmed: 25769213
Ball MW, Gorin MA, Bhayani SB, Rogers CG, Stifelman MD, Kaouk JH et al (2015) Preoperative predictors of malignancy and unfavorable pathology for clinical T1a tumors treated with partial nephrectomy: a multi-institutional analysis. Urol Oncol 33(3):112.e9–14
doi: 10.1016/j.urolonc.2014.11.003 pubmed: 25499258
Deng X, Liu X, Hu B, Jiang M, Zhu K, Nie J et al (2022) Pathological diagnostic nomograms for predicting malignant histology and unfavorable pathology in patients with endophytic renal tumor. Front Oncol 12:964048
doi: 10.3389/fonc.2022.964048 pubmed: 36212405 pmcid: 9532530
Nagahara A, Uemura M, Kawashima A, Ujike T, Fujita K, Miyagawa Y et al (2016) R.E.N.A. L nephrometry score predicts postoperative recurrence of localized renal cell carcinoma treated by radical nephrectomy. Int J Clin Oncol 21:367–372
doi: 10.1007/s10147-015-0879-3 pubmed: 26219992
Mouracade P, Kara O, Maurice MJ, Dagenais J, Malkoc E, Nelson RJ et al (2017) Patterns and predictors of recurrence after partial nephrectomy for kidney tumors. J Urol 197(6):1403–1409
doi: 10.1016/j.juro.2016.12.046 pubmed: 27993666
Vartolomei MD, Matei DV, Renne G, Tringali VM, Crisan N, Musi G et al (2019) Robot-assisted partial nephrectomy: 5-yr oncological outcomes at a single european tertiary cancer center. Eur Urol Focus 5(4):636–641
doi: 10.1016/j.euf.2017.10.005 pubmed: 29111154
Vickers AJ, Elkin EB (2006) Decision curve analysis: a novel method for evaluating prediction models. Med Decis Mak Int J Soc Med Decis Mak 26(6):565–574
doi: 10.1177/0272989X06295361
Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED et al (2003) Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97(7):1663–1671
doi: 10.1002/cncr.11234 pubmed: 12655523
Muramaki M, Miyake H, Sakai I, Kondo Y, Kusuda Y, Yamada Y et al (2011) Age at diagnosis as a powerful predictor for disease recurrence after radical nephrectomy in Japanese patients with pT1 renal cell carcinoma. Int J Urol Off J Jpn Urol Assoc 18(2):121–125
Patel HD, Johnson MH, Pierorazio PM, Sozio SM, Sharma R, Iyoha E et al (2016) Diagnostic accuracy and risks of biopsy in the diagnosis of a renal mass suspicious for localized renal cell carcinoma: systematic review of the literature. J Urol 195(5):1340–1347
doi: 10.1016/j.juro.2015.11.029 pubmed: 26901507 pmcid: 5609078
Yang G, Nie P, Yan L, Zhang M, Wang Y, Zhao L et al (2022) The radiomics-based tumor heterogeneity adds incremental value to the existing prognostic models for predicting outcome in localized clear cell renal cell carcinoma: a multicenter study. Eur J Nucl Med Mol Imaging 49(8):2949–2959
doi: 10.1007/s00259-022-05773-1 pubmed: 35344062
Kikuchi H, Abe T, Matsumoto R, Osawa T, Maruyama S, Murai S et al (2019) Nephrometry score correlated with tumor proliferative activity inT1 clear cell renal cell carcinoma. Urol Oncol 37(5):301.e19-301.e25
doi: 10.1016/j.urolonc.2019.02.005 pubmed: 30826166
Kutikov A, Smaldone MC, Egleston BL, Manley BJ, Canter DJ, Simhan J et al (2011) Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol 60(2):241–248
doi: 10.1016/j.eururo.2011.03.029 pubmed: 21458155 pmcid: 3124570

Auteurs

Martin Lorette (M)

Department of Urology, Lille University Hospital, Lille, France. martin6lorette@gmail.com.
Service d'Urologie, Hôpital Claude Huriez, Rue Michel Polonowski, 59037, Lille, France. martin6lorette@gmail.com.

Jean-Christophe Bernhard (JC)

Department of Urology, University Hospital, Bordeaux, France.

Charles-Karim Bensalah (CK)

Department of Urology, Rennes University Hospital, Rennes, France.

Pierre Bigot (P)

Department of Urology, University Hospital, Angers, France.

Arnauld Villers (A)

Department of Urology, Lille University Hospital, Lille, France.
Department of Urology, University Hospital, Lille, France.

Marie Lou Letouche (ML)

Department of Urology, University Hospital, Tours, France.

Nicolas Doumerc (N)

Department of Urology, University Hospital of Rangueil, Toulouse, France.

Philippe Paparel (P)

Department of Urology, University Hospital, Lyon Sud, France.

François Audenet (F)

Department of Urology, Georges Pompidou European University Hospital, Paris, France.

François-Xavier Nouhaud (FX)

Department of Urology, University Hospital, Rouen, France.

Bastien Parier (B)

Department of Urology, Kremlin Bicetre University Hospital, Paris, France.

Thibault Tricard (T)

Department of Urology, University Hospital, Strasbourg, France.

Cécile Champy (C)

Department of Urology, Mondor University Hospital, Créteil, France.

Martin Brenier (M)

Department of Urology, St Joseph Hospital, Paris, France.

Géraldine Pignot (G)

Department of Urology, Paoli-Calmettes Institute, Marseille, France.

Jean-Alexandre Long (JA)

Department of Urology, University Hospital, Grenoble, France.

Matthieu Durand (M)

Department of Urology, University Hospital, Nice, France.

Maxime Vallee (M)

Department of Urology, University Hospital, Poitiers, France.

Thibaut Waeckel (T)

Department of Urology, University Hospital, Caen, France.

Romain Boissier (R)

Department of Urology, University Hospital, Marseille, France.

Ricky Tambwe (R)

Department of Urology, University Hospital, Reims, France.

Idir Ouzaid (I)

Department of Urology, Bichat University Hospital, Paris, France.

Jonathan Olivier (J)

Department of Urology, Lille University Hospital, Lille, France.

Zine-Eddine Khene (ZE)

Department of Urology, Rennes University Hospital, Rennes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH